KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Alnylam Pharmaceuticals (ALNY) Receivables - Other (2018 - 2021)

Alnylam Pharmaceuticals' Receivables - Other history spans 3 years, with the latest figure at $500.0 million for Q2 2021.

  • For Q2 2021, Receivables - Other changed N/A year-over-year to $500.0 million; the TTM value through Jun 2021 reached $500.0 million, changed N/A, while the annual FY2020 figure was $500.0 million, N/A changed from the prior year.
  • Receivables - Other reached $500.0 million in Q2 2021 per ALNY's latest filing, roughly flat from $500.0 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $500.0 million in Q3 2020 to a low of $12.5 million in Q4 2018.
  • Average Receivables - Other over 3 years is $402.5 million, with a median of $500.0 million recorded in 2020.